Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts
Authors:
- Meghan E. McGee-LawrenceMMMeghan E. McGee-Lawrence
- Angela L. McCleary-WheelerAMAngela L. McCleary-Wheeler
- Frank J. SecretoFSFrank J. Secreto
- David F. RazidloDRDavid F. Razidlo
- Minzhi ZhangMZMinzhi Zhang
- Bridget A. StensgardBSBridget A. Stensgard
- Xiaodong LiXLXiaodong Li
- Gary S. SteinGSGary S. Stein
- Jane B. LianJLJane B. Lian
- Jennifer J. WestendorfJWJennifer J. Westendorf
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- The Histone Deacetylase Inhibitor, Vorinostat, Reduces Tumor Growth at the Metastatic Bone Site and Associated Osteolysis, but Promotes Normal Bone LossMolecular Cancer Therapeutics, 2010
- Histone Deacetylase 3 Depletion in Osteo/Chondroprogenitor Cells Decreases Bone Density and Increases Marrow FatPLOS ONE, 2010
- Redundant Control of Adipogenesis by Histone Deacetylases 1 and 2Journal of Biological Chemistry, 2010
- Assessment for the identification of better HDAC inhibitor class through binding energy calculations and descriptor analysisBioinformation, 2008
- Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell LymphomaJournal of Clinical Oncology, 2007
- Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitorsJournal of Cellular Biochemistry, 2005
- Repression of Runx2 function by TGF‐β through recruitment of class II histone deacetylases by Smad3The EMBO Journal, 2005
- Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine ResidueScience, 2005
- Histone Deacetylase 3 Interacts with Runx2 to Repress the Osteocalcin Promoter and Regulate Osteoblast DifferentiationJournal of Biological Chemistry, 2004
- Deacetylation of p53 modulates its effect on cell growth and apoptosisNature, 2000